Table 5.
Haplotype | Controls | OA patients | ||||
Total | Women | Men | Total | Women | Men | |
TAG | 0.41 | 0.44 | 0.37 | 0.41 | 0.42 | 0.40 |
TAA | 0.09 | 0.12 | 0.05 | 0.17 | 0.18 | 0.14 |
TGG | 0.09 | 0.09 | 0.08 | 0.05 | 0.05 | 0.05 |
TGA | 0.03 | 0.03 | 0.02 | <0.01 | <0.01 | <0.01 |
CAG | 0.25 | 0.18 | 0.31 | 0.18 | 0.18 | 0.18 |
CAA | 0.06 | 0.06 | 0.06 | 0.05 | 0.04 | 0.07 |
CGG | 0.06 | 0.06 | 0.08 | 0.10 | 0.10 | 0.09 |
CGA | 0.02 | 0.01 | 0.02 | 0.04 | 0.02 | 0.07 |
df = 7, χ2 = 21.48; Pa = 0.003 | df = 7, χ2 = 8.22; Pa = 0.314 | df = 7, χ2 = 16.76; Pa = 0.019 |
A total of 397 control individuals and 151 osteoarthritis (OA) patients were included in the study. Values given are haplotype frequencies. aP values for overall difference in haplotype distribution between OA patients and control individuals were calculated using the EH program [23]. df, degrees of freedom.